US Patent

US11801253 — Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease

Method of Use · Assigned to Opko Renal LLC · Expires 2030-09-07 · 4y remaining

Vulnerability score 76/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating and preventing secondary hyperparathyroidism in chronic kidney disease by administering Vitamin D hormone replacement therapy.

USPTO Abstract

A method of treating and preventing secondary hyperparathyroidism in CKD by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering 25-hydroxyvitamin D3 with or without 25-hydroxyvitamin D2 and, as necessary, 1,25-dihydroxyvitamin D2 as a Vitamin D hormone replacement therapy.

Drugs covered by this patent

Rayaldee (CALCIFEDIOL)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3721`	—	Rayaldee

Patent Metadata

Patent number: US11801253
Jurisdiction: US
Classification: Method of Use
Expires: 2030-09-07
Drug substance claim: No
Drug product claim: Yes
Assignee: Opko Renal LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.